Compare Globus Medical Inc. Class A Common Stock (GMED) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs ResMed Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while ResMed Inc. trades at $236.19 (market cap $33.09B). The key difference: ResMed Inc. is far larger — about 3.2× Globus Medical Inc. Class A Common Stock's market cap, and ResMed Inc. pays a 1.12% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and ResMed Inc. for 51 Days on average.
| GMED | RMD | |
|---|---|---|
Market Cap | $10.25B | $33.09B |
Volume | 1,059,528 | 1,019,685 |
Sector | Health | Health |
52-Week High | $96.82 | $275.96 |
52-Week Low | $58.33 | $182.82 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $9.76B | $32.45B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ResMed (RMD) trades at $235.04, up 0.19% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $243.56. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding expectations. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%, while cash flow from operations reached $1.75B. Recent news highlights upcoming Q1 2027 earnings and a Morgan Stanley conference presentation focusing on growth targets.
The outlook for RMD is positive, driven by consistent earnings outperformance, high profitability, and institutional buying interest. Key opportunities include market share gains and product innovation in sleep therapy, though risks involve competitive pressures and ongoing legal investigations. The stock's current valuation metrics, including a P/E of 22.56, appear reasonable relative to growth, supporting a constructive view for investors seeking exposure to healthcare equipment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
